Immune response differs between intralymphatic or subcutaneous administration of GAD‐alum in individuals with recent onset type 1 diabetes-Reference-Cited by-同舟云学术

Immune response differs between intralymphatic or subcutaneous administration of GAD‐alum in individuals with recent onset type 1 diabetes

Published:2021-10-12 Issue: Volume: Page:
ISSN:1520-7552
Container-title:Diabetes/Metabolism Research and Reviews
language:en
Short-container-title:Diabetes Metab Res Rev

Author:

Dietrich Fabrícia¹^ORCID,Barcenilla Hugo¹,Tavira Beatriz¹,Wahlberg Jeanette²³⁴,Achenbach Peter⁵⁶,Ludvigsson Johnny¹⁷^ORCID,Casas Rosaura¹

Affiliation:

1. Division of Pediatrics Department of Biomedical and Clinical Sciences Faculty of Medicine and Health Sciences Linköping University Linköping Sweden

2. Department of Endocrinology in Linköping Linköping University Linköping Sweden

3. Department of Health, Medicine and Caring Sciences Linköping University Linköping Sweden

4. Faculty of Medical Sciences Örebro University Örebro Sweden

5. Institute of Diabetes Research Helmholtz Zentrum München Munich Germany

6. Forschergruppe Diabetes School of Medicine Technical University of Munich Munich Germany

7. Crown Princess Victoria Children’s Hospital Linköping Sweden

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/dmrr.3500

Reference28 articles.

1. Correlating the global increase in type 1 diabetes incidence across age groups with national economic prosperity: A systematic review

2. New Frontiers in the Treatment of Type 1 Diabetes

3. Combination immunotherapies for type 1 diabetes mellitus

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antigen-specific T cell responses in autoimmune diabetes;Frontiers in Immunology;2024-08-15

2. Az 1-es típusú diabetes mellitus immunterápiája;Orvosi Hetilap;2024-03-10

3. A 1‐year pilot study of intralymphatic injections of GAD‐alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes;Diabetes, Obesity and Metabolism;2023-08-14

4. Monitoring islet specific immune responses in type 1 diabetes clinical immunotherapy trials;Frontiers in Immunology;2023-05-22

5. Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype;Frontiers in Immunology;2023-02-02